Neoadjuvant chemoimmunotherapy combo shows promise in UTUC
The phase 2 study explored the combination of the PD-1 inhibitor toripalimab and chemotherapy as neoadjuvant treatment for patients with upper tract urothelial carcinoma.
Darolutamide is well tolerated in patients with mCRPC over long term
No grade 3 TEAEs were reported in more than 1 patient at a time, and investigators deemed these grade 3 TEAEs to be unrelated to darolutamide treatment.
Final survival analysis shows significant boost with enzalutamide in mHSPC
The final results from the phase 3 ARCHES trial showed that the addition of enzalutamide to androgen deprivation therapy also continued to improve radiologic progression-free survival and other secondary end points.
Researchers look to neoadjuvant setting to advance RCC paradigm
Naomi B. Haas, MD, discusses efforts to improve care in locally advanced renal cell carcinoma through research in the neoadjuvant setting.
2 Clarke Drive Cranbury, NJ 08512